• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Visus Therapeutics adds to ophthalmic drug portfolio, licenses delivery tech

August 19, 2021 By Sean Whooley

Visus TherapeuticsVisus Therapeutics announced today that it entered into worldwide licensing agreements with Cella Therapeutics and DelSiTech.

The exclusive worldwide licensing agreement with Cella covers the development of investigational ophthalmic therapies for treating glaucoma and age-related macular degeneration (AMD). The additional worldwide exclusive licensing agreement with DelSiTech will lead to the development of novel drug delivery technology to help optimize the clinical benefit of ophthalmic therapies.

According to a news release, under the agreement with Cella Therapeutics, Visus will advance preclinical development programs targeting elevated intraocular pressure, neuroprotection and neuroenhancement in patients with glaucoma and geographic atrophy secondary to AMD.

With DelSiTech, Visus will develop investigational treatments for intraocular administration using a biodegradable, silica-based, sustained-release technology designed to overcome the limitations of currently available ophthalmic therapies through the consistent drug release over an extended period of time, as well as the ability to dissolve as the drug is released, leaving no residue in the eye.

“By expanding our portfolio to include investigational drugs for glaucoma and age-related macular degeneration and leveraging this innovative drug delivery technology, Visus Therapeutics is well-positioned to develop a new generation of therapies that could potentially change the standard of care for these sight-threatening conditions,” Visus co-founder & CEO Ben Bergo said in the release. “This represents a significant step forward in our strategy as we evolve into an innovation-focused ophthalmic company armed with differentiated, patent-protected assets driven by a world-class leadership team.”

Visus develops Brimochol, its lead investigational drug candidate for treating presbyopia, and VTI-003, a preclinical asset with corneal wound healing applications. The company expects topline data from a Phase 2 trial later this year, with potential Phase 3 pivotal studies set to start before the end of 2021.

“The synergistic nature of Cella’s novel, investigational therapeutics for glaucoma and geographic atrophy in combination with DelSiTech’s innovative drug delivery technology has the potential to yield profound advancements in the treatments of these very serious eye diseases,” Visus co-founder, CMO & head of R&D Dr. Rhett Schiffman said. “Our seasoned team of scientists have dedicated their lives’ work to the discovery and development of sight-preserving treatments. The addition of these assets to the Visus Therapeutics portfolio enables our team to harness their collective expertise in pursuit of dramatically improving patient outcomes.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: Visus Therapeutics

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS